Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Agent Orange Exposure Does Not Predict for Shorter Overall Survival in Patients with Chronic Lymphocytic Leukemia: A National Veteran Affairs Tumor Registry Study

Craig Mescher, MD, Nicole Randall, MD, Gobind Tarchand, Lisa M. Baumann Kreuziger, MD MS, Dave Gilbertson, Julie Tomaska, Vicki A. Morrison, MD

Blood (2016) 128 (22): 5568.

https://doi.org/10.1182/blood.V128.22.5568.5568

Published: 2016

Journal Articles

Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d’Etude De Lymphome d’Adultes

Ranjana H. Advani, MD, Fangxin Hong, PhD, Thomas M. Habermann, MD, Hailun Li, MS, Brad S. Kahl, MD, Vicki A. Morrison, MD, Edie A. Weller, PhD, Gaurav Varma, MSPH, Richard I Fisher, MD, Bruce A. Peterson, MD, Bruce D. Cheson, M.D., Randy D. Gascoyne, MD, Sandra J. Horning, MD, Sami Bousetta, Bertrand Coiffier, MD, PhD, Marita Ziepert, Michael Pfreundschuh, MD

Blood (2013) 122 (21): 3045.

https://doi.org/10.1182/blood.V122.21.3045.3045

Published: 2013

Journal Articles

The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience

Fangxin Hong, Ph.D., Thomas M Habermann, MD, Leo I. Gordon, MD, Howard S Hochster, MD, Randy D. Gascoyne, MD, Vicki A. Morrison, MD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Patrick J Stiff, MD, Bruce D. Cheson, M.D., Michael Crump, MD FRCPC, Sandra J. Horning, MD, Brad S. Kahl, MD

Blood (2013) 122 (21): 3060.

https://doi.org/10.1182/blood.V122.21.3060.3060

Published: 2013

Journal Articles

The Impact of Agent Orange Exposure On Presentation and Prognosis of Patients with Chronic Lymphocytic Leukemia (CLL): An Exploratory Analysis

Lisa M Baumann Kreuziger, MD, Vicki A. Morrison, MD

Blood (2012) 120 (21): 4575.

https://doi.org/10.1182/blood.V120.21.4575.4575

Published: 2012

Journal Articles

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Vicki A. Morrison, MD, Sin-Ho Jung, PhD, Jeffrey Johnson, MS, Ann LaCasce, MD, Kristie A. Blum, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD

Blood (2012) 120 (21): 3696.

https://doi.org/10.1182/blood.V120.21.3696.3696

Published: 2012

Journal Articles

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Thomas M Habermann, MD, Fangxin Hong, PhD, Vicki A. Morrison, MD, Shaker R. Dakhil, MD, James K. Weick, MD, Stanley R. Frankel, MD, Randy D. Gascoyne, MD, Richard I Fisher, MD, Bruce D. Cheson, MD, Edie A. Weller, PhD, Brad S. Kahl, M.D., Bruce A. Peterson, MD, Howard S Hochster, MD, Sandra J. Horning, M.D.

Blood (2012) 120 (21): 3705.

https://doi.org/10.1182/blood.V120.21.3705.3705

Published: 2012

Journal Articles

Common variation at 6p21.31 ( BAK1 ) influences the risk of chronic lymphocytic leukemia

Blood (2012) 120 (4): 843–846.

https://doi.org/10.1182/blood-2012-03-413591

Published: 2012

Includes: Supplemental data

Journal Articles

Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL

Blood (2011) 117 (6): 1911–1916.

https://doi.org/10.1182/blood-2010-09-308205

Published: 2011

Includes: Supplemental data

Journal Articles

Herpes Zoster (HZ) Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphoma: An Analysis of Two Phase II Trials.

Vicki A. Morrison, MD, Richard I Fisher, MD, Andre Goy, MD, Sven de Vos, Steven H. Bernstein, Anthony Boral, MD, PhD, Rachel Neuwirth, MS

Blood (2010) 116 (21): 2818.

https://doi.org/10.1182/blood.V116.21.2818.2818

Published: 2010

Journal Articles

R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793

Vicki A. Morrison, MD, Fangxin Hong, PhD, Thomas M. Habermann, MD, Richard I. Fisher, MD, Bruce D. Cheson, MD, Brad Kahl, MD, Sandra J. Horning, MD, Bruce A. Peterson, MD

Blood (2010) 116 (21): 589.

https://doi.org/10.1182/blood.V116.21.589.589

Published: 2010

Journal Articles

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

Blood (2010) 116 (21): 2443.

https://doi.org/10.1182/blood.V116.21.2443.2443

Published: 2010

Journal Articles

Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.

Blood (2009) 114 (22): 1232.

https://doi.org/10.1182/blood.V114.22.1232.1232

Published: 2009

Journal Articles

Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

Kanti R. Rai, MD, Bercedis L. Peterson, Ph.D, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Andrew Belch, MD, Vicki A. Morrison, MD, Richard A. Larson, MD

Blood (2009) 114 (22): 536.

https://doi.org/10.1182/blood.V114.22.536.536

Published: 2009

Journal Articles

Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.

Jennifer A Woyach, MD, Amy S Ruppert, Nyla A. Heerema, PhD, Bercedis Peterson, Ph.D, John G. Gribben, MD, DSc, Vicki A. Morrison, MD, Kanti R Rai, MD, Richard A. Larson, MD, John C. Byrd, MD

Blood (2009) 114 (22): 539.

https://doi.org/10.1182/blood.V114.22.539.539

Published: 2009

Journal Articles

Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).

Vicki A. Morrison, MD, Bercedis L. Peterson, PhD, Kanti R. Rai, MD, John C. Byrd, MD, Richard A. Larson, MD

Blood (2007) 110 (11): 756.

https://doi.org/10.1182/blood.V110.11.756.756

Published: 2007

Journal Articles

Patients with Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy with First and Subsequent Cycle Pegfilgrastim Support Experience Low Rates of Neutropenic Complications: Preliminary Results of FIRST, a Prospective Community-Based Study.

Howard Ozer, MD, PhD, Stephen J. Noga, MD, PhD, Vicki A. Morrison, MD, Beiying Ding, PhD, Roger Dansey, MD

Blood (2005) 106 (11): 4705.

https://doi.org/10.1182/blood.V106.11.4705.4705

Published: 2005

Journal Articles

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

John C. Byrd, Kanti Rai, Bercedis L. Peterson, Frederick R. Appelbaum, Vicki A. Morrison, Jonathan E. Kolitz, Lois Shepherd, John D. Hines, Charles A. Schiffer, Richard A. Larson

Blood (2005) 105 (1): 49–53.

https://doi.org/10.1182/blood-2004-03-0796

Published: 2005

Journal Articles

Patterns of Growth Factor (GF) Usage and Febrile Neutropenia (FN) among Older Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP or R-CHOP: An Intergroup Experience (CALGB 9793, ECOG-SWOG 4494).

Vicki A. Morrison, MD, Edie A. Weller, PhD, Thomas M. Habermann, MD, Shuli Li, MS, Sandra J. Horning, MD, Richard I. Fisher, MD, Bruce A. Peterson, MD

Blood (2004) 104 (11): 3309.

https://doi.org/10.1182/blood.V104.11.3309.3309

Published: 2004

Journal Articles

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

John C. Byrd, Bercedis L. Peterson, Vicki A. Morrison, Kathleen Park, Robert Jacobson, Eva Hoke, James W. Vardiman, Kanti Rai, Charles A. Schiffer, Richard A. Larson

Blood (2003) 101 (1): 6–14.

https://doi.org/10.1182/blood-2002-04-1258

Published: 2003

NARROW

Agent Orange Exposure Does Not Predict for Shorter Overall Survival in Patients with Chronic Lymphocytic Leukemia: A National Veteran Affairs Tumor Registry Study

The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience

The Impact of Agent Orange Exposure On Presentation and Prognosis of Patients with Chronic Lymphocytic Leukemia (CLL): An Exploratory Analysis

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Common variation at 6p21.31 ( BAK1 ) influences the risk of chronic lymphocytic leukemia

Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL

Herpes Zoster (HZ) Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphoma: An Analysis of Two Phase II Trials.

R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793

Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci

Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.

Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.

Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).

Patients with Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy with First and Subsequent Cycle Pegfilgrastim Support Experience Low Rates of Neutropenic Complications: Preliminary Results of FIRST, a Prospective Community-Based Study.

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

Patterns of Growth Factor (GF) Usage and Febrile Neutropenia (FN) among Older Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP or R-CHOP: An Intergroup Experience (CALGB 9793, ECOG-SWOG 4494).

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only